Document is current
Any future updates will be listed below
-
Authors
Burns, Kharis
Mullin, Benjamin H.
Moolhuijsen, Loes M. E.
Laisk, Triin
Tyrmi, Jaakko S.
Cui, Jinrui
Actkins, Ky’Era V.
Louwers, Yvonne V.
,
Metspalu, Andres
Milani, Lili
Esko, Tõnu
Nelis, Mari
Hudjashov, Georgi
Davis, Lea K.
Dudbridge, Frank
Azziz, Ricardo
Goodarzi, Mark O.
Laivuori, Hannele
Mägi, Reedik
Visser, Jenny A.
Laven, Joop S. E.
Wilson, Scott G.
,
,
Karaderi, Tugce
Jones, Michelle R.
Meun, Cindy
He, Chunyan
Drong, Alex
Kraft, Peter
Lin, Nan
Huang, Hongyan
Broer, Linda
Saxena, Richa
Metspalu, Andres
Milani, Lili
Esko, Tõnu
Nelis, Mari
Hudjashov, Georgi
Urbanek, Margrit
Hayes, M. Geoffrey
Thorleifsson, Gudmar
Fernandez-Tajes, Juan
Mahajan, Anubha
Spector, Timothy D.
Obermayer-Pietsch, Barbara
Uitterlinden, André G.
Anttila, Verneri
Neale, Benjamin M.
Jarvelin, Marjo-Riitta
Daly, Mark
Fauser, Bart
Kowalska, Irina
Andersen, Marianne
Ong, Ken
Stener-Victorin, Elisabet
Ehrmann, David
Legro, Richard S.
Salumets, Andres
McCarthy, Mark I.
Morin-Papunen, Laure
Thorsteinsdottir, Unnur
Stefansson, Kari
,
Styrkarsdottir, Unnur
Perry, John R. B.
Dunaif, Andrea
Franks, Steve
Lindgren, Cecilia M.
Welt, Corrine K.
Day, Felix R.
Stuckey, Bronwyn G. A.
- License Information
-
More Information
Article History
Received: 2 May 2023
Accepted: 8 January 2024
First Online: 26 February 2024
Declarations
:
: All subjects in the study provided written informed consent and the experimental protocols were approved for individual cohorts as follows:Cedars Sinai -The study was approved by the institutional review boards of the recruiting centers and Cedars-Sinai Medical Center (CSMC). Written informed consent was obtained from all participants. BioVU – Approved by the Institutional Review Board at Vanderbilt University (#160279).WA-PCOS by the SCGOPHCG Human Research Ethics Committee (RGS0000001467) and controls by HRA North West – Liverpool East Research Ethics Committee (19/NW/0187; TwinsUK).-Estonian Biobank—All biobank participants have signed a broad informed consent form and analyses were carried out under ethical approval 1.1–12/624 from the Estonian Committee on Bioethics and Human Research (Estonian Ministry of Social Affairs) and data release N05 from the EstBB.-FinnGen—Patients and control subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea (Finnish Medicines Agency), the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) statement number for the FinnGen study is Nr HUS/990/2017.The FinnGen study is approved by Finnish Institute for Health and Welfare (permit numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019 and THL/1524/5.05.00/2020), Digital and population data service agency (permit numbers: VRK43431/2017–3, VRK/6909/2018–3, VRK/4415/2019–3), the Social Insurance Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 134/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA 16/522/2020), Findata permit numbers THL/2364/14.02/2020, THL/4055/14.06.00/2020,,THL/3433/14.06.00/2020, THL/4432/14.06/2020, THL/5189/14.06/2020, THL/5894/14.06.00/2020, THL/6619/14.06.00/2020, THL/209/14.06.00/2021, THL/688/14.06.00/2021, THL/1284/14.06.00/2021, THL/1965/14.06.00/2021, THL/5546/14.02.00/2020 and Statistics Finland (permit numbers: TK-53–1041-17 and TK/143/07.03.00/2020 (earlier TK-53–90-20)).The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 7 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26, BB2020_1, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, Auria Biobank AB17-5154 and amendment #1 (August 17 2020), Biobank Borealis of Northern Finland_2017_1013, Biobank of Eastern Finland 1186/2018 and amendment 22 § /2020, Finnish Clinical Biobank Tampere MH0004 and amendments (21.02.2020 & 06.10.2020), Central Finland Biobank 1–2017, and Terveystalo Biobank STB 2018001.- Rotterdam—The Rotterdam PCOS cohort, was approved by institutional review board (Medical Ethics Committee) of the Erasmus Medical Center (04–263).Controls from the Lifelines Cohort Study have been approved by the UMCG Medical ethical committee under number 2007/152.All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: The FinnGen project is funded by the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb (and Celgene Corporation & Celgene International II Sarl), Genentech Inc., Merck Sharp & Dohme Corp., Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, Novartis AG, and Boehringer Ingelheim International GmbH. All other authors declare that they have no competing interests.
